Anaphylaxis is an acute and potentially lethal multisystem allergic reaction. Most consensus guidelines for the past 30 years have held that epinephrine is the drug of choice and the first drug that should be administered in acute anaphylaxis. Some state that properly administered epinephrine has no absolute contraindication in this clinical setting. A committee of anaphylaxis experts assembled by the World Allergy Organization has examined the evidence from the medical literature concerning the appropriate use of epinephrine for anaphylaxis. The committee strongly believes that epinephrine is currently underused and often dosed suboptimally to treat anaphylaxis, is underprescribed for potential future self-administration, that most of the reasons proposed to withhold its clinical use are flawed, and that the therapeutic benefits of epinephrine exceed the risk when given in appropriate intramuscular doses.
CITATION STYLE
Kemp, S. F., Lockey, R. F., & Simons, F. E. R. (2008). Epinephrine: The Drug of Choice for Anaphylaxis--A Statement of the World Allergy Organization. World Allergy Organization Journal, 1, S18–S26. https://doi.org/10.1186/1939-4551-1-s2-s18
Mendeley helps you to discover research relevant for your work.